2023 World Conference on Lung Cancer (Posters)-EP07.05. Aumolertinib as Neoadjuvant Therapy for EGFR-mutated Non-Small Cell Lung Cancer: A Subcohort Analysis of the PURPOSE Trial

EP07.05. Aumolertinib as Neoadjuvant Therapy for EGFR-mutated Non-Small Cell Lung Cancer: A Subcohort Analysis of the PURPOSE Trial - PDF(Slides)

Back to course

Pdf Summary

The study analyzed the effectiveness of Aumolertinib as neoadjuvant therapy for patients with EGFR-mutated Non-Small Cell Lung Cancer (NSCLC) in the PURPOSE trial. Aumolertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). The primary endpoint of the trial was the objective response rate (ORR) according to RECIST v1.1 criteria. Secondary endpoints included pathological complete response (pCR), major pathologic response (MPR), event-free survival (EFS), disease-free survival (DFS), overall survival (OS), complete resection (R0) rate, estimation of surgical outcomes, and safety. An exploratory endpoint was the investigation of patient-specific minimal residual disease (MRD) in predicting treatment efficacy and prognosis.<br /><br />The results showed that all six patients who completed the neoadjuvant treatment and underwent radical surgery achieved an ORR of 100% and an R0 resection rate of 100%. Other notable findings include an 83.3% mediastinal lymph node downstage and an MPR of 50%, with a pCR of 33.3% (including one squamous cell carcinoma case). The safety profile of Aumolertinib was acceptable, with only one patient experiencing Grade 1 oral ulceration. No other intraoperative or postoperative complications were reported.<br /><br />In conclusion, the subcohort analysis from the PURPOSE trial demonstrated that Aumolertinib as neoadjuvant therapy is effective and feasible for locally-advanced EGFR 19del NSCLCs. The study acknowledges the participation of patients, their families, caregivers, and the study team members, as well as all staff involved in the trial. Future findings from the study will be released.

Asset Subtitle

Yi-Yang Wang

Meta Tag

Speaker Yi-Yang Wang

Topic Early-Stage NSCLC: Pushing the Boundaries

Keywords

Aumolertinib

neoadjuvant therapy

EGFR-mutated NSCLC

PURPOSE trial

objective response rate

pathological complete response

event-free survival

surgical outcomes

minimal residual disease

locally-advanced NSCLCs